Helix BioPharma Corp.

Helix BioPharma Corp.

HBPCF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$58.81M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Helix BioPharma Corp.Helix BioPharma Corp.-19.3--24%-0.3
$-0.03

Current Fair Value

104% downside

Overvalued by 104% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$58.81 Million
Enterprise Value$62.17 Million
Earnings per Share$-0.04
Beta-0.35
Outstanding Shares76,378,098

Return

Return on Equity-23.60%ROE
Return on Assets-17.31%
Return on Invested Capital-26.20%

Valuation & Multiples

P/E Ratio-19.32P/E Ratio
PEG-611.74PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-16.7
Enterprise Value to Net Income-19
Total Debt to Enterprise0.07
Debt to Equity0.29Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
October 29, 2026
EPS
-$0.01
Est. -$0.08
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
December 10, 2026
EPS Estimate
-$0.08
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Helix BioPharma Corp.

7 employees
CEO: Thomas Mehrling

Helix BioPharma Corp. is a Canadian enterprise focused on immuno-oncology. The company's research and development efforts include L-DOS47, a drug candidate aimed at treating non-small cell lung cancer, and V-DOS47, which is designed to i...